Please note that this product was withdrawn from the Community register of designated orphan medicinal products in April 2013 on request of the sponsor.
On 27 October 2011, orphan designation (EU/3/11/918) was granted by the European Commission to Bristol-Myers Squibb Pharma EEIG, United Kingdom, for brivanib alaninate for the treatment of hepatocellular carcinoma.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
|Disease / condition||
Treatment of hepatocellular carcinoma
|Date of first decision||
|EU designation number||
Review of designation
Please note that this product was withdrawn from the Community register of designated orphan medicinal products in April 2013 on request of the sponsor, before a marketing authorisation had been granted.
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.